Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 4/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.49 |
| ▸ | CDK2 | P24941 | 2/20 | 0.49 |
| ▸ | JAK2 | O60674 | 3/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 2/20 | 0.47 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.47 |
| ▸ | CDK7 | P50613 | 1/20 | 0.47 |
| ▸ | CCNH | P51946 | 1/20 | 0.47 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.47 |
| ▸ | ACVR1 | Q04771 | 10/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.43 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5090939 | 0.90 | FLT3 (0.60) | FLT3CCNE1CDK2JAK2JAK3 | |
| SCHEMBL5103647 | 0.89 | ACVR1 (0.53) | JAK2JAK3PTK2ACVR1AIMP2 | |
| SCHEMBL5090865 | 0.89 | JAK2 (0.48) | FLT3CCNE1CDK2JAK2JAK3 | |
| SCHEMBL5097325 | 0.87 | FLT3 (0.55) | FLT3CCNE1CDK2JAK2JAK3 | |
| SCHEMBL4628222 | 0.87 | JAK2 (0.54) | FLT3CCNE1CDK2JAK2JAK3 | |
| SCHEMBL4629688 | 0.86 | JAK2 (0.50) | FLT3CCNE1CDK2JAK2JAK3 | |
| SCHEMBL5103235 | 0.80 | JAK2 (0.58) | JAK2JAK3ACVR1AIMP2 | |
| SCHEMBL5094765 | 0.78 | CDK2 (0.56) | FLT3CCNE1CDK2JAK2JAK3 | |
| SCHEMBL5094669 | 0.78 | ACVR1 (0.57) | JAK2JAK3PTK2ACVR1AIMP2 | |
| SCHEMBL5103237 | 0.78 | JAK2 (0.50) | CDK2JAK2JAK3PTK2ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242667-A1 | Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases | SMITHKLINE BEECHAM CORPORATION | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242667-A1 | Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases | AURKA, AURKC, PLK1 | FLT3 152/4885CCNE1 159/4885CDK2 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.